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Abstract
Background:  Real-time quantitative PCR (RQ-PCR) forms the basis of many breast cancer
biomarker studies and novel prognostic assays, paving the way towards personalised cancer
treatments. Normalisation of relative RQ-PCR data is required to control for non-biological
variation introduced during sample preparation. Endogenous control (EC) genes, used in this
context, should ideally be expressed constitutively and uniformly across treatments in all test
samples. Despite widespread recognition that the accuracy of the normalised data is largely
dependent on the reliability of the EC, there are no reports of the systematic validation of genes
commonly used for this purpose in the analysis of gene expression by RQ-PCR in primary breast
cancer tissues. The aim of this study was to identify the most suitable endogenous control genes
for RQ-PCR analysis of primary breast tissue from a panel of eleven candidates in current use.
Oestrogen receptor alpha (ESR1) was used a target gene to compare the effect of choice of EC on
the estimate of gene quantity.
Results: The expression and validity of candidate ECs (GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0,
B2M, GUSB, MRPL19, PUM1 and PSMC4) was determined in 6 benign and 21 malignant primary
breast cancer tissues. Gene expression data was analysed using two different statistical models.
MRPL19 and PPIA were identified as the most stable and reliable EC genes, while GUSB, RPLP0 and
ABL were least stable. There was a highly significant difference in variance between ECs. ESR1
expression was appreciably higher in malignant compared to benign tissues and there was a
significant effect of EC on the magnitude of the error associated with the relative quantity of ESR1.
Conclusion: We have validated two endogenous control genes, MRPL19 and PPIA, for RQ-PCR
analysis of gene expression in primary breast tissue. Of the genes in current use in this field, the
above combination offers increased accuracy and resolution in the quantitation of gene expression
data, facilitating the detection of smaller changes in gene expression than otherwise possible. The
combination identified here is a good candidate for use as a two-gene endogenous control in a
broad spectrum of future research and diagnostic applications in breast cancer.
Published: 27 November 2007
BMC Molecular Biology 2007, 8:107 doi:10.1186/1471-2199-8-107
Received: 15 June 2007
Accepted: 27 November 2007
This article is available from: http://www.biomedcentral.com/1471-2199/8/107
© 2007 McNeill et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Molecular Biology 2007, 8:107 http://www.biomedcentral.com/1471-2199/8/107
Page 2 of 13
(page number not for citation purposes)
Background
Breast cancer is the most common form of malignancy
among women in almost all of Europe and in North
America. Each year over one million women worldwide
are diagnosed with the disease and it causes over 400,000
deaths annually. Much of the current translational
research in this area is based on "transcriptomics", the elu-
cidation of the transcriptional programs underlying dis-
ease initiation, promotion and progression, through
tumour gene expression profiling. Real-time quantitative
PCR (RQ-PCR) [1,2] is one of the most sensitive and spe-
cific quantitation methods for gene expression analysis
and is firmly established as a mainstream research tool [3-
5]. With the development of high throughput and reliable
instrumentation, improved detection chemistries, more
efficient protocols and appropriate analysis software, RQ-
PCR has become the basis of many breast cancer biomar-
ker studies as well as several novel diagnostic and prog-
nostic assays [6-12]. In addition, RQ-PCR is used to
validate microarray expression profiles and quantify genes
of interest identified from those analyses.
The most commonly used method to quantify gene
expression involves the analysis of target gene expression
relative to a control gene. As in other relative gene expres-
sion analysis techniques such as Northern blotting and
ribonuclease protection assays (RPAs), normalisation of
RQ-PCR data is required to control for variation intro-
duced during the steps from RNA extraction to quantita-
tion, especially to control for differences in the quantity
and quality of RNA used in reactions [13]. The use of
endogenous control (EC) genes, known variously as
housekeepers, reference or simply control genes is based
on the principle that these genes are expressed constitu-
tively and uniformly in all test samples, so that expression
of the target gene can be normalised against them to con-
trol for systematic variation in sample handling. Results
are then expressed as the ratio of target gene expression
relative to the EC gene. In many cases, control genes are
inherited from earlier studies using less sensitive forerun-
ner techniques such as Northern blotting and little if any
consideration has been paid to validating these genes as
controls for specific experiments.
Two of the most commonly used endogenous control
genes for breast cancer gene expression studies are glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) and β-
actin (ACTB) but their reliability in this context has not
been demonstrated. In some studies the use of either gene
may be inappropriate, as these genes have been impli-
cated in aspects of disease aetiology [14-20]. For example,
bisphosphonates; used to inhibit bone resorption in dis-
eases including osteoporosis, Paget's disease and meta-
static breast cancer, target GAPDH, decreasing its
expression in both breast and prostate cell lines [21],
while the actin filament protein family, of which ACTB is
a member, may be modulated in malignancy [22] partic-
ularly during processes involving reorganisation of the
cytoskeleton such as invasion and migration.
The precision of the estimate of change in target gene
expression is dependent on the stability of the endog-
enous control, the variability associated with the target
gene and any covariance between the two. Thus the use of
non-validated endogenous control genes results in, at
best, unreliable data. It is now recognised that a universal,
invariably expressed gene is unlikely to exist [23] and may
not exist even within individual tissue or cell types. The
goal therefore is to identify the most reliable gene or set of
genes as endogenous controls for a particular experiment.
As a result of this, several groups have developed statistical
models and software programs for the analysis of candi-
date gene stability. The aim of this study was to identify
the most stable endogenous control genes from a panel of
eleven candidates commonly used as endogenous con-
trols in the context of, but not limited to, breast cancer:
GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB,
MRPL19, PUM1, PSMC4, for the quantification of gene
expression by relative comparative RQ-PCR in primary
breast cancer tissues. The oestrogen receptor alpha (ESR1)
transcript, a gene of special significance in breast cancer,
was used as a target gene to compare the effect of choice
of EC on the estimate of gene quantity.
Results
To identify suitable EC genes for breast cancer gene
expression studies in fresh-frozen primary tissue, a panel
of 11 genes commonly used as ECs was selected from the
literature for analysis of stability: GAPDH, TFRC, ABL,
PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and
PSMC4. Genes were analysed in tumours recovered from
patients with benign or malignant breast disease using
RQ-PCR. Stability of candidate EC genes was analysed
using two statistical analysis tools, geNorm and
NormFinder, which employ different statistical models to
define the most reliable EC genes for normalisation. The
effect of choice of EC gene on target gene expression was
analysed using ESR1 as target.
Range of expression of candidate EC genes and ESR1
The candidate ECs displayed a range of Ct values. Mean Ct
values per gene and the range of Ct values for each gene are
shown in Table 1. Mean Ct values ranged from 19.13 (±
0.21 s.e.m.) for B2M  to 26.48 (± 0.15 s.e.m.) for
MRPL19.MRPL19 showed the narrowest range followed
by PPIA. The genes broadly fell into two categories, those
highly expressed with mean Ct values of 19–20 (B2M,
RPLP0, GAPDH, PPIA) and moderate abundance genes
with mean Ct values of 23–26 (PSMC4, ABL, GUSB, TFRC,
PUM1, HPRT1 and  MRPL19). The target gene ESR1BMC Molecular Biology 2007, 8:107 http://www.biomedcentral.com/1471-2199/8/107
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showed the broadest range of Ct values (10.35) from
17.10–27.45.
With conversion of Ct values to relative quantity values
(QRel.), there was no difference in candidate EC gene
quantities between benign and malignant tissues (P  >
0.05; Fig. 1a). There was however, a significant difference
in variance between genes (P = 0.001; Fig. 1b) indicative
of differing stabilities of the candidates.
Analysis of EC gene stability
The significant difference in EC variability demonstrated
the necessity to validate their use in this context. Expres-
sion stability was analysed using the two softwares
geNorm [24,25] and NormFinder [26].
GeNorm uses a pair-wise comparison-based model to
select from a panel of candidate EC genes, the gene-pair
showing least variation in expression ratio across samples.
It calculates a measure of gene stability (M) of each gene
based on the average pairwise variation between all tested
genes. Genes with the lowest M values are those demon-
strating most stable expression. Table 2 shows the M val-
ues for all tested genes. Eight of the eleven genes analysed;
PPIA, MRPL19, GAPDH, PUM1, B2M, HPRT1, PSMC4 and
TFRC, showed M  values less than the geNorm default
threshold of 1.5, while the three remaining genes; RPLP0,
GUSB and ABL, showed M values greater than that thresh-
old. In a stepwise progression, geNorm excludes the least
stable gene, recalculating M  for the remaining genes,
resulting in the characterisation of the stability of each
gene on a ranked scale and ultimately the identification of
the two most stably expressed genes (Fig. 2a). As
shown,ABL and GUSB were the first and second genes
respectively excluded from the analysis on the basis of
instability and MRPL19 and PPIA were identified as most
stable gene-pair.
GeNorm also calculates a normalisation factor (NF)
required to determine the optimal number of EC genes
required for accurate normalisation. This factor is calcu-
lated using the variable V as the pairwise variation (Vn/Vn
+ 1) between two sequential NFs (NFn and NFn + 1). To
meet the recommended cut off V-value of 0.15, the point
at which it is unnecessary to include additional genes in a
normalisation strategy [24], the programme indicated the
use of 5 of the six most stable genes i.e., MRPL19, PPIA,
GAPDH, PUM1 and B2M (Fig. 2b). However, there was no
significant effect on relative quantity of ESR1 expression
using the 5 gene panel of MRPL19, PPIA, B2M GAPDH
and PUM1, compared to the two-gene combination of
MRPL19 and PPIA (P > 0.05).
Stability of gene expression was also analysed using
NormFinder [26]. This programme uses a combined esti-
mate of the intra- and inter-group variation to determine
the most stably expressed candidate EC gene and gene-
pair. Table 2 shows the ranking of the candidates. As for
geNorm, NormFinder identified MRPL19 and PPIA as the
most stable pair of genes and MRLP19 as the single most
stable gene.
Associations between candidates EC genes and ESR1
The geNorm programme assumes no co-regulation of can-
didate ECs as obviously this would lead to an erroneous
choice of optimum normaliser pair. As stated above, to
our knowledge the candidate ECs tested in this study are
functionally independent. In addition co-variance
between target gene and EC would affect results. Regres-
sion analysis demonstrated significant, negative, linear
Table 1: Cycle threshold (Ct) values of candidate EC genes and ESRI. Among the candidate ECs, MRPL19 and PPIA showed the smallest 
range in Ct values while GAPDH, HPRT1, and RPLP0 showed the greatest. Candidates fell into two groups in terms of abundance, high 
(Ct 19–20; B2M, RPLP0, GAPDH and PPIA) and moderate abundance (Ct 23–26; PSMC4, ABL, GUSB, TFRC, PUM1, HPRT1 and MRPL19). 
ESR1 ranged over 10.35 Ct values
Gene symbol Ct Range CtMin. CtMax. Mean Ct ± s.e.m.
MRPL19 4.06 24.79 28.84 26.48 ± 0.15
PPIA 4.4 18.01 22.41 19.74 ± 0.18
B2M 4.67 17.22 21.89 19.13 ± 0.21
PUM1 5.06 22.38 27.44 24.78 ± 0.21
GUS 5.19 21.37 26.55 23.94 ± 0.20
PSMC4 5.69 20.84 26.52 23.32 ± 0.22
ABL 5.89 21.27 27.15 23.75 ± 0.30
TFRC 6.03 21.4 27.42 24.40 ± 0.29
GAPDH 6.88 16.79 23.67 19.71 ± 0.25
HPRT1 7.05 21.57 28.61 24.84 ± 0.27
RPLPO 8.8 16.1 24.9 19.46 ± 0.33
ESR1 10.35 17.10 27.45 21.96 ± 0.34BMC Molecular Biology 2007, 8:107 http://www.biomedcentral.com/1471-2199/8/107
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Relative quantity and variation associated with each candidate EC Figure 1
Relative quantity and variation associated with each candidate EC. a) Quantity of candidate endogenous control 
genes GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4 in benign and malignant breast tumour 
tissue relative to calibrator (QRel. = E-ΔCt). Boxplot shows median value, interquartile-range box and outliers (*). Within gene 
there was no difference in gene quantities between benign and malignant tissues (P > 0.05). b) Variation associated with candi-
date endogenous control genes GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4 in all breast 
tumours relative to calibrator. Relative gene expression was calculated using the ΔCt method and corrected for efficiency of 
amplification (QRel. = E-ΔCt). There was a significant difference in variance associated with relative gene expression (P = 0.001) 
with genes such as RPLP0, TRFC, HPRT1 and GAPDH showing greater variance than genes such as MRPL19 and PPIA.
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associations between the relative quantities (QRel.) of the
target gene, ESR1  and two commonly used ECs; TFRC
(TFRC = 0.079 - 0.272 ESR1; R2 = 0.18; P < 0.05) and
HPRT1 (HPRT1 = - 0.202 - 0.386 ESR1; R2 = 0.35; P =
0.001). In addition there was a significant linear associa-
tion between QRel. of ESR1  and  ABL  described by the
equation: ABL = 0.044 + 0.290 ESR1; R2 = 0.21;P = 0.012.
There was no association between ESR1  and either
MRPL19 or PPIA (P > 0.05).
Effect of EC on ESR1 relative gene expression
There was no effect of choice of EC on the relative quantity
of ESR1 (P > 0.05) probably due to the large variation
associated with the expression of ESR1 compared to any
GeNorm analysis of the candidate EC genes Figure 2
GeNorm analysis of the candidate EC genes. Results are presented as per the output file of the geNorm programme 
[24]. (a) Stepwise exclusion of the least stable genes. The gene stability value M is based on the average pairwise variation 
between all tested genes. Low M values characterise genes with greater stability, thus the x-axis from left to right indicates the 
ranking of the EC genes according to expression stability and the y-axis indicates the stability measure, M. (b) Determination of 
the optimal number of ECs for normalisation. The recommended upper limit of the pairwise variation value V is set at 0.15 but 
in meeting this criterion, sample availability, the practicality of using multiple EC genes and the degree of required resolution 
must be considered.
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of the EC genes as shown in Fig. 3. However, there was a
significant effect of EC gene on the estimate of the error
associated with relative gene expression (P < 0.05). The
magnitude of the error was significantly reduced using
MRL19  and  PPIA  as a combined endogenous control
compared to the use of ABL, B2M, GAPDH, GUSB, HPRT1,
PSMC4, PPIA, PUM1, RPLP0 and TFRC. While there was
no difference in error using MRPL19 and PPIA in combi-
nation compared to MRPL19 on its own (P > 0.05), there
was a trend towards a reduction in the estimate of the
error using the combined normalising factor. There was a
significant increase in relative quantity of ESR1 in malig-
nant versus benign breast tissues compared to normal
breast tissue (P < 0.01; Fig. 4).
Discussion
To our knowledge this is the first systematic evaluation of
the reliability of a large number of genes used as endog-
enous controls for RQ-PCR analysis in breast cancer stud-
ies. The literature cites just two articles in relation to the
evaluation of EC genes for breast cancer [27,28]. How-
ever, one study characterised ECs not in primary breast tis-
sues but in cell lines [27] and the other, while employing
primary breast tissues, compared just two commonly used
EC genes with other genes selected from a microarray
dataset of breast cancer tissues and cell lines, as well as cell
lines of different origins [28].
Quantitative PCR is the basis of most nucleic acid-based
breast cancer biomarker studies and its potential clinical
utility is foretold by the development of the Oncotype Dx
assay (Genomic Health). This 21-gene assay can predict
metastatic recurrence [11] and magnitude of response to
chemotherapy [29] in Tamoxifen-treated ER-positive early
breast cancer patients. RQ-PCR will undoubtedly feature
prominently in the move toward personalised medicine
so the necessity of validating ECs in clinical samples as
opposed to cell lines is clear. The diversity of the tissues
used in this study in terms of histological and clinical
parameters (Table 3) makes the results of interest to a
broad spectrum of the breast cancer research community.
With the exception of ABL, used as an EC in other settings
[30], genes were selected for evaluation based their prior
use in breast cancer studies, to determine the most reliable
EC of those used in this field. Certain genes were excluded
based on evidence that their use in this context is inappro-
priate [20,22,31-33].
Validation of EC genes raises the circular issue of how to
normalise normalising genes. This issue governs the valid-
ity of the conclusions of such studies so at each stage of
this experiment sources of non-biological variation were
minimised and data were scaled relative to a calibrator.
Quantity of all genes expressed in breast tissues relative to  calibrator (QRel Figure 3
Quantity of all genes expressed in breast tissues rela-
tive to calibrator (QRel. = E-ΔCt). A pool of cDNA from 
two normal tissues was used as calibrator.
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Table 2: Expression stability values of EC genes calculated by geNorm and NormFinder programmes
NormFinder geNorm
Rank Gene Stabilityb Gene Stability
1 MRPL19 0.105 PPIA 1.116
2 PPIA 0.119 MRPL19 1.134
3 B2M 0.169 GAPDH 1.240
4 GAPDH 0.176 PUM1 1.275
5 PUM1 0.222 B2M 1.305
6 HPRT1 0.233 HPRT1 1.357
7 TFRC 0.236 PSMC4 1.419
8 PSMC4 0.247 TFRC 1.437
9 GUSB 0.268 RPLPO 1.549
10 RPLPO 0.295 GUSB 1.568
11 ABL 0.413 ABL 2.070
bHigh expression stability is indicated by a low stability value. For geNorm, stability is based on an estimate of the pairwise variation (M) relative 
expression while for NormFinder, stability is based on combined inter- and intra-group variation.BMC Molecular Biology 2007, 8:107 http://www.biomedcentral.com/1471-2199/8/107
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For example, RNA integrity, quality and purity were strin-
gently analysed. A threshold RIN value of 7 was applied,
below which samples were excluded from analysis. This
aspect is of importance given the relationship between
RNA integrity and expression quantitation [34-36]. Dupli-
cate cDNA reactions were performed and genes were
amplified in triplicate using more stringent cut-offs for
replicate variability than recommended elsewhere [37]. In
addition, the efficiency of amplification of each assay was
determined (Table 4) and data were corrected appropri-
ately. Determination of assay efficiency is critical in com-
paring gene expression [38] but has not been addressed in
similar studies [39]. Cycle threshold (Ct) data were scaled
relative a pooled normal tissue calibrator. Similar studies
describe the comparison of genes based on raw Ct values
[40,41], an inappropriate approach as discussed below
and elsewhere [36].
There was no effect of tissue type on EC expression, vali-
dating comparison of their stability. This is an essential
but often overlooked precursor analysis when using
geNorm and NormFinder [42] since these methodologies
assume the candidates are not differentially expressed
between experimental groups. There was however a signif-
icant difference in variance between candidates (P  =
0.001; Fig. 1), with genes such as RPLP0, TRFC, HPRT1
and  GAPDH  showing greater variance than others e.g.,
MRPL19  and  PPIA. Since the resolution of RQ-PCR is
defined by the variance associated with the EC [13] these
results emphasise the necessity to evaluate and validate
EC genes.
A single universal EC is unlikely to exist [43] and since the
function of most genes is largely unknown it is impossible
to predict their expression under different experimental
conditions. The use of more than one EC hedges the bet
and increases the accuracy of quantitation compared to
the use of a single EC [13,24,26,36,44]. Studies show sub-
stantial errors, up to 6.5-fold, in expression quantitation
using single as opposed to multiple EC genes [24]. In this
study, stability of expression was analysed using two dis-
tinct statistical models, a pairwise comparison model,
geNorm, and an ANOVA-based model, NormFinder. The
geNorm applet selects from a panel of genes, the pair
showing least variation in expression ratio across samples
and estimates the minimum number of genes required for
optimal normalisation. NormFinder estimates stability
values for ECs considering combined intra- and inter-
Relative quantity of oestrogen receptor alpha mRNA (ESR1) in benign and malignant breast tumour tissue Figure 4
Relative quantity of oestrogen receptor alpha mRNA (ESR1) in benign and malignant breast tumour tissue. 
Quantity of gene expression was calculated relative to each candidate endogenous control gene and to the geometric mean of 
MRPL19 and PPIA (QRel. = E-ΔΔCt ± s.e.m.). A pool of cDNA from two normal tissues was used as calibrator. There was no 
effect of EC on the relative quantity of ESR1 in either group (P > 0.05), however, there was a significant effect of EC gene on 
the estimate of the error associated with relative gene expression (P < 0.05). The error was significantly reduced using the 
combination of MRL19 and PPIA compared to the use of all EC genes individually with the exception of MRPL19.
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group variation and identifies the most stable gene and
gene-pair, where the stability of the pair exceeds that of
the single gene. Despite their differences both models
identified  MRPL19  and  PPIA  as the most reliable ECs
while  RPLP0,  GUSB  and  ABL  were least reliable. This
result reflects those of the equality of variance analysis
and, broadly, ranking by range of Ct values (Table 2).
However, the ranking of genes by Ct range and by the
model-based methods differed for some genes e.g.,
GAPDH, demonstrating the necessity to scale and correct
raw Cts for amplification efficiency before analysis.
GeNorm indicated that optimal normalisation could be
achieved using the five most stable genes but there was no
difference in ESR1 gene expression using this approach as
opposed to the two-gene combination. While it is not
known whether this would hold for other less variable tar-
get genes, cost and sample availability are limiting factors
for most studies so the two-gene combination may be
more practical for most applications.
The effect of using less stable ECs was assessed using ESR1
as a target gene. Due to the high variability of the expres-
sion of this gene (Fig. 4) there was no effect of EC on
quantitation. Without further discussion of the relevance
of the differential expression of ESR1 in benign and malig-
nant tissues; a gene whose role in breast cancer is widely
appreciated, it is likely that had the target gene shown a
more discreet change in gene expression, an effect of EC
on quantitation would have been apparent. There was
however a clear tendency for ESR1 expression to change
depending on EC (Fig. 4). In the benign samples ESR1
could be made to appear up- or down-regulated depend-
ing on EC, while its expression in the malignant samples
could be numerically altered by one order of magnitude –
Table 3: Clinical and histological data relating to the benign (Ben.) and malignant (Mal.) breast tissues. Data includes patient 
menopausal status and histological type, and tumour size, T, N, M, UICC stage, grade, ER, PR and HER2/neu status and intrinsic 
subtype of malignant tissues where available
Tissue type Size (mm) T N M UICC Grade Menopausal status Histological type Subtype ER PR HER2/neu
Mal. 35 2 1 0 2B 3 pre ductal
Mal. 22 2 1 0 2B 2 post ductal luminal A 8 4 negative
Mal. 22 2 0 0 2B 3 pre ductal basal 0 0 negative
Mal. 25 2 0 0 2A pre ductal unknown
Mal. 37 2 1 0 2B 3 pre ductal luminal A 8 8 negative
Mal. 35 2 1 0 2B 1 pre lobular luminal A 7 8 negative
Mal. 45 2 1 0 2B 3 pre ductal basal 0 0 negative
Ben. pre fibrocystic
Mal. 20 1 1 0 2A 1 post ductal luminal A 8 8 negative
Mal. 50 2 1 0 2B 3 post ductal luminal B 8 3 positive
Mal. 15 1 1 0 2A 2 post ductal luminal A 8 3 negative
Mal. 20 1 0 0 1 2 post ductal luminal A 8 8 negative
Mal. 25 4 1 0 3B 3 post ductal luminal B 4 4 positive
Mal. 10 1 0 0 1 post ductal, some tubular luminal A 8 8 negative
Mal. 33 2 1 0 2B 1 post lobular luminal A 8 8 negative
Mal. 30 2 1 0 2B 3 pre ductal luminal A 7 8 negative
Mal. 30 2 1 0 2B 3 pre ductal 0 0
Mal. 20 1 1 post colloid/mucinous
Mal. 40 2 1 0 2B 2 post lobular luminal B 8 0 positive
Ben.
Ben. pre fibroadenoma
Ben. pre parenchymal 
inflammation
Mal. 35 4 2 0 3B 3 post ductal luminal A 8 8 negative
Mal. 35 2 1 0 2B 3 post ductal luminal A 8 6 negative
Mal. pre ductal luminal A 7 0 negative
Mal. 25 2 0 0 2A 2 pre ductal Her2 0 0 positive
Mal. 60 4 2 1 4 2
Ben. pre
Ben. pre fibroadenoma
Abbreviations: T: size or extent of primary tumour; N: spread to regional lymph nodes; M: distant metastasis; UICC, tumour stage according to the 
International Union Against Cancer TNM classification; ER: oestrogen receptor status; PR: progesterone receptor status; HER2/neu: v-erb-b2 
erythroblastic leukaemia viral oncogene status.BMC Molecular Biology 2007, 8:107 http://www.biomedcentral.com/1471-2199/8/107
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artifactual results due simply to the choice of EC. Clearly
this type of error is unacceptable, especially in the analysis
of markers for potential clinical application.
Furthermore, there was a significant effect of EC on the
magnitude of the error associated with the estimate of
ESR1 expression. The use of the MRPL19, PPIA combina-
tion minimised the error compared to all other ECs with
the exception of MRPL19. Apart from the fact that the use
of single EC genes can compromise data as already
described, the use of either gene alone is not recom-
mended for two further reasons. Firstly, geNorm identi-
fied them based on a pairwise comparison model so their
individual use is inconsistent with that analysis method.
As shown in Fig. 4, ESR1 expression can be made numer-
ically increase or decrease in the benign groups if these
genes are used singly. Secondly, stability, as assessed by
NormFinder, increased roughly 30 percentage points,
from 0.105 using MRPL19 alone to 0.072 using it in com-
bination with PPIA indicating improved reliability of the
two-gene combination [26].
One previous study analysed EC stability in primary
breast tissue [28]. That study compared two traditionally
used ECs, GAPDH and ACTB and four genes identified in
microarray studies [45,46]: MRPL19, PUM1, PSMC4 and
SF3A1. The authors recommended MRPL19 be used with
PSMC4 and PUM1. However, in the present study, PPIA,
which was not assessed by Szabo and colleagues, showed
greater stability than PSMC4 and PUM1. Of the genes ana-
lysed in this study, PPIA  ranked first and second by
Normfinder and geNorm respectively compared to fifth
and seventh for PSMC4 and eighth and fourth for PUM1.
The reason(s) PPIA  did mot emerge as a candidate in
Szabo and colleagues' microarray study is unclear. As part
of their selection procedure, data was filtered to remove
near background signals from low abundance genes yet in
this study PPIA showed the third highest mean Ct value.
Cohort-specific effects are also unlikely since the tissues
are broadly similar in terms of their clinical and histolog-
ical parameters. Apart from the obvious differences in the
quantitative capacities of microarray and RQ-PCR tech-
nology, a possible explanation is that the cohort from
which these authors selected their candidates was not
breast cancer-specific and included tissue from metastatic
breast cancer lymph nodes and cell lines from an assort-
ment of origins including dermal, leukemic, umbilical
and melanoma samples [46].
This study also analysed associations between genes. An
assumption of the geNorm model is that candidate ECs
are not co-regulated yet the analysis of such genes by that
method would lead to an erroneous choice of best gene-
pair. To our knowledge the EC genes evaluated here are
functionally independent as shown in Table 4. In addi-
tion, covariance of target and EC is clearly unacceptable.
However, regression analysis showed significant linear
relationships between ESR1 and three of the candidates:
TFRC,  HPRT1  and  ABL. Approximately two thirds of
breast tumours are oestrogen-dependent and the number
of genes whose expression is known to be, or likely to be
mediated through the receptor is sizeable [47]. This makes
analysis of associations between oestrogen-responsive tar-
get and control genes of particular importance in breast
cancer studies. Although there is little evidence that these
genes are regulated by oestrogen, the results suggest that
Table 4: Details of gene-specific RQ-PCR assays
Gene symbol Gene name Molecular function Applied 
Biosystems assay 
identifier
Amplicon
size (bp)
Slope of
inhibition
curve
PCR
Amplification
efficiency (%)
ABL Abelson murine leukaemia 
viral 1
non-receptor tyrosine 
protein kinase
Hs00245443_m1 54 -3.47 93.9
B2M Beta-2-microglobulin defense/immunity protein 4333766 75 -3.48 93.6
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase
oxidoreductase, 
dehydrogenase
4333764 168 -3.52 92.3
GUSB Glucuronidase, beta galactosidase 4333767 63 -3.38 97.3
HPRT1 Hypoxanthine guanine 
phosphoribosyl transferase 1
glycosyltransferase 4333768 100 -3.37 97.7
MRPL19 Mitochondrial ribosomal 
protein L19
protein biosynthesis Hs00608519_m1 72 -3.14 107.7
PPIA Peptidylprolyl isomerase A isomerase Hs99999904_m1 98 -3.38 97.3
PSMC4 Proteasome 26S subunit, 
ATPase, 4
protease, hydrolase Hs00197826_m1 83 -3.38 97.6
PUM1 Pumilio, Drosophila, homolog 
of, 1
RNA binding, translation 
regulation
Hs00982776_m1 62 -3.30 100.7
RPLP0 Ribosomal protein, large, P0 protein biosynthesis 4333761 154 -3.51 92.7
TFRC Transferrin receptor ion receptor 4333770 130 -3.56 90.9
ESR1 Oestrogen receptor alpha nuclear steroid receptor Hs00174860_m1 62 -3.45 94.5BMC Molecular Biology 2007, 8:107 http://www.biomedcentral.com/1471-2199/8/107
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aside from their poor stability it would be wise not to use
them as ECs in the analysis of oestrogen-responsive breast
cancer.
Despite the clear increase in accuracy afforded by the use
of more than one validated EC gene, a recent survey of
working practices indicated that over half of those polled
continue to use one reference gene and that two thirds of
these do not validate that gene [48]. Obviously levels of
awareness and/or willingness to address this issue must be
improved.
Conclusion
The current emphasis on personalised cancer treatment
has resulted in the development of prognostic and predic-
tive multi-gene RQ-PCR assays. However, with such devel-
opments comes the demand for greater accuracy and
resolution of gene expression quantitation. In this study
we have validated two genes, MRPL19 and PPIA as EC can-
didates for RQ-PCR analysis of primary breast tissue using
two different statistical models and demonstrate that of
the genes in current use in this field, the above gene com-
bination offers increased accuracy and resolution in the
relative quantitation of gene expression data. The genes
identified should be of use in a broad spectrum of trans-
lational research and diagnostic applications in breast
cancer.
Methods
Breast tissue samples
Primary breast tumour tissues (n = 27) were obtained
from patients during primary curative resection, at Galway
University Hospital, Galway, Ireland. Samples were cate-
gorised into benign (n = 6) or malignant groups (n = 21)
according to analysis of standard histopathological
parameters. Clinical data relating to the tumour tissues
used in this study are shown in Table 3. RNA from normal
tissues, recovered from patients undergoing reduction
mastopexy were used as calibrator samples for compara-
tive relative RQ-PCR (n = 2). After excision, tissue samples
were immediately snap-frozen in liquid nitrogen and
stored at -80°C until RNA extraction. Prior written and
informed consent was obtained from each patient and the
study was approved by the ethics review board of Galway
University Hospital. Clinical data were obtained from the
Breast Cancer Database at the Department of Surgery, Gal-
way University Hospital.
Candidate endogenous control genes
Eleven commonly used candidate endogenous control
genes were selected for analysis (Table 4). To our knowl-
edge, all genes are constitutively expressed in breast cancer
tissues and all have independent cellular functions and
are assumed not to be co-regulated. Only RPLP0  and
MRPL19 share a molecular function, i.e., protein biosyn-
thesis.
Minimisation of non-biological variation
While target gene expression is normalised using EC genes
to correct for variation introduced during sample process-
ing using, this is obviously not possible in EC validation
studies. Since this critical issue governs the reliability of
the data generated and the validity of the conclusions it
was addressed as described below.
Firstly, while it was not possible to control for variation in
the acquisition of clinical samples collected over a
number of years, every effort was made to minimise sys-
tematic variation downstream of sample acquisition. All
equipment and instruments were calibrated before use.
Benign and malignant samples were homogenised sepa-
rately but on the same day. All RNA was extracted using
the same protocol and reagent lot by one person to avoid
batch-to-batch variation. Where possible, two extractions
from separate areas of the each tissue sample were pooled
to control for tissue heterogeneity. RNA integrity and
purity were stringently analysed as described below.
Duplicate cDNA reactions were performed to minimise
variation from the reverse transcription step. No-RT con-
trols were included with each batch of cDNA synthesised.
All PCR reactions were performed on the same pool of
aliquotted cDNA and no-template controls were included
in each run for each gene. Appropriate inter-assay controls
were included in each run. In addition, the efficiency of
amplification was calculated for each assay and expres-
sion results were corrected for the small differences in effi-
ciency observed between genes (Table 4). All cycle
threshold (Ct) data was scaled relative to a calibrator sam-
ple amplified using the same gene.
Total RNA Isolation
Tissue (50–100 mg) was homogenised in 1 ml of QIAzol
Lysis Reagent (Qiagen, Crawley, UK), using a bench-top
homogeniser (Polytron PT1600E, Kinematica AG, Littau-
Luzem, Switzerland). Total RNA was isolated from
homogenised breast tissue using the RNeasy® Tissue Mini
Kit (Qiagen, Crawley, UK) according to the manufac-
turer's instructions. RNA was eluted in 60 μl nuclease-free
water and stored at -80°C. In addition to the on-column
DNase treatment performed during the RNA extraction
procedure, RNA was DNase-treated after extraction using
the DNA-free™ DNase Treatment and Removal Reagents
(Ambion, Cambridgeshire, UK). RNA concentration and
purity was assessed in duplicate samples using a Nano-
drop ND-1000 spectrophotometer (Nanodrop Technolo-
gies, DE, USA). RNA integrity was assessed using the RNA
6000 Nano LabChip Series II Assay with the 2100 Bioan-
alyzer System (Agilent Technologies, Palo Alto, CA, USA).
Electropherograms and gel-like images were evaluatedBMC Molecular Biology 2007, 8:107 http://www.biomedcentral.com/1471-2199/8/107
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using the Agilent 2100 Expert software (Version B.02.03)
which generated the RNA integrity number (RIN) ena-
bling estimation of RNA integrity. The RIN value describes
a graded scale of RNA integrity ranging from 1 (com-
pletely degraded total RNA) to 10 (intact total RNA).
Based on this tool, total RNA integrity is determined not
only by the ratio of the ribosomal bands but by the entire
electrophoretic trace of the sample including presence or
absence of degradation products [49].
In agreement with recent reports [34,35], there was a sig-
nificant negative linear relationship between RNA integ-
rity, as determined by analysis of RIN and Ct values (P <
0.05), with increased Ct values associated with RIN less
than 5 (data not shown). Therefore the threshold RIN
value for inclusion of RNA samples in analysis was ≥ 7.
RNA purity was verified by an average A260/A280 ratio of
1.98, ranging from 1.97 to 2.01. A260/A230 ratios averaged
1.7, ranging from 1.5 to 1.83.
First strand cDNA synthesis by reverse transcription
First strand cDNA was synthesised in duplicate reactions
for each RNA sample (2 by 1 μg each) using Superscript III
reverse transcriptase (Invitrogen Life Technologies, Pais-
ley, UK) and random primers (N9; 1 μg; MWG Biotech,
AG, Ebersberg, Germany). Negative controls consisting of
non-reverse transcribed samples were included in each set
of reactions. The reactions were incubated at 25°C for 5
min followed by 50°C for 1 h and finally 72°C for 15
min. Duplicate cDNA reactions were pooled, diluted to
120 μl in nuclease-free water (Invitrogen Life Technolo-
gies), aliquotted and stored at -20°C till further use.
Real-time Quantitative PCR
The expression of the 11 candidate EC genes was analysed
by RQ-PCR using TaqMan® Endogenous Control Assays or
TaqMan® Gene Expression Assays and the ABI Prism® 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA). Each gene was tested in triplicate within the
same PCR run for the majority of samples, with the
remaining samples tested on an additional 96-well plate.
TaqMan® Endogenous Control Assay and Gene Expression
Assay IDs are listed in Table 4. Samples with standard
deviations >0.3 from the mean Ct of the triplicates were
excluded from analysis. HPRT1, amplified from pooled
normal cDNA, was run on each plate to assess inter-assay
variation. cDNA (2 μl) from each tumour sample was
added to a PCR reaction mix containing 1× TaqMan® Uni-
versal PCR Master Mix, No AmpErase® UNG and 1 μl
Endogenous Control Assay or Gene Expression Assay
(Applied Biosystems) in a 20 μl reaction volume. Stand-
ard cycling conditions were used [95°C for 10 minutes,
(95°C for 15 seconds, 60°C for 60 seconds) × 40 cycles].
The inter-assay percent coefficient of variation (%CV) for
samples with a mean Ct of 25.81 ± 0.07 (mean ± s.e.m.)
was 0.81% (n = 15).
PCR amplification efficiencies
Percent PCR amplification efficiencies (E) for each assay
were calculated as E = (10-1/slope - 1) × 100, using the slope
of the semi-log regression plot of Ct versus log input of
cDNA (10-fold dilution series of five points) as shown in
Table 4. A threshold of 10% above or below 100% effi-
ciency was applied. Amplification efficiencies ranged
from 90.9% for TFRC to 107.7% for MRPL19, indicative
of approximate exponential efficiencies for these assays.
Conversion of cycle threshold (Ct) to quantity relative to 
calibrator
The baseline (3–15 cycles) and average threshold cycle
(Ct) were automatically calculated using the ABI Prism
SDS Software (version 1.2.3). The Ct value is defined as
the PCR cycle number at which the fluorescence generated
from amplification of the target gene within a sample
increases to a threshold value of 10 times the standard
deviation of the baseline emission and is inversely pro-
portional to the starting amount of target cDNA. Ct results
were converted into quantities relative to normal (QRel.),
and corrected for PCR amplification efficiency (E), using
the following formula: QRel. = E-ΔCt, where ΔCt = Ct test
sample – Ct calibrator sample.
Comparative quantitation of target gene ESR1 relative to 
endogenous control
To calculate the expression of ESR1, relative to an EC
gene(s), the ΔΔCt method was used where ΔΔCt = (Ct tar-
get gene, test sample – Ct endogenous control, test sam-
ple) - (Ct target gene, calibrator sample - Ct endogenous
control, calibrator sample). Fold change in gene expres-
sion between groups was calculated as E-ΔΔCt ± s.e.m.
Where target gene expression was normalised using more
than one endogenous control, fold change estimates were
calculated using the geometric mean of EC quantities rel-
ative to the calibrator sample and the errors were calcu-
lated following the rules of error propagation descibed
previously [25].
Analysis of EC stability
Candidate EC gene stability was evaluated using two sta-
tistical models for the analysis candidate EC genes,
geNorm [[24], Ver. 3.4] and NormFinder [26]. Ct values
were converted into relative quantities considering the
PCR amplification efficiencies as detailed above. GeNorm
is a Visual Basic application tool for Microsoft® Excel and
is freely available by request from the authors [50].
NormFinder is a Microsoft® Excel add-in, also freely avail-
able [51]. For NormFinder analysis tissues samples were
categorised into benign (n = 6) or malignant groups (n =BMC Molecular Biology 2007, 8:107 http://www.biomedcentral.com/1471-2199/8/107
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21) according to analysis of standard histopathological
parameters as described above.
Statistical analyses
Statistical analyses were performed with Minitab® 15 Sta-
tistical Software for Windows® (Minitab Ltd., Coventry,
UK). P values <0.05 were considered statistically signifi-
cant. The Anderson-Darling normality test was applied.
Two-sample t tests were used to compare calibrator-scaled
EC gene quantities between benign and malignant tissue
groups. Equality of variance between scaled EC QRel. val-
ues and effect of EC on the estimate of the error associated
with gene expression was analysed using Bartlett's test.
Associations between scaled EC and target gene quantities
were determined by regression analysis which examined
linear, quadratic and cubic relationships. One-way
ANOVA was used to compare ESR1 expression normal-
ised using different EC genes.
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